Navigation Links
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
Date:10/24/2011

HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, November 1, 2011.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 1, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

22066672To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 22066672. The audio replay will be available until November 8, 2011.  

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
3. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
6. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
7. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
10. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
11. Omega Protein Announces Retention of Lipid Technologies, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... favorable programs deployed by the government are expected to ... market" The gesture recognition market is expected ... at a CAGR of 29.63% between 2017 and 2022. ... USD 15.27 billion by 2022, growing at a CAGR ...
(Date:3/29/2017)... 29, 2017 WuXi Biologics, a leading ... to biologics and a WuXi AppTec Affiliate, today ... Best Bioprocessing Excellence Award from IMAPAC, a leading ... aims to recognize outstanding leaders and trend-setters of ... bioprocessing and biomanufacturing experts in the industry, along ...
(Date:3/29/2017)... ... 29, 2017 , ... (March 29, 2017) — Nerium ... as an active member of the Mexican Direct Selling Association A.C. (AMVD ... in relationship marketing. This professional organization fosters loyal and fair competition among companies ...
(Date:3/29/2017)... 2017  Applied BioMath ( www.appliedbiomath.com ), ... drug research and development, today announced an ... for quantitative systems pharmacology (QSP) support for ... treatment of cancer. Applied ... toxicology studies and first-in-human dose predictions for ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:3/1/2017)... Mass. , March 1, 2017  Aware, Inc. ... services, announced that Richard P. Moberg has ... and co-President and Chief Financial Officer and Treasurer of ... continue to serve as a member of the Board ... Russell , Aware,s co-Chief Executive Officer and co-President, General ...
Breaking Biology News(10 mins):